<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2022.891994</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>A Robust Method to Store Complement C3 With Superior Ability to Maintain the Native Structure and Function of the Protein</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Adler</surname>
<given-names>Anna</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/880958"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Manivel</surname>
<given-names>Vivek Anand</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/878964"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fromell</surname>
<given-names>Karin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/878414"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Teramura</surname>
<given-names>Yuji</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ekdahl</surname>
<given-names>Kristina&#xa0;N.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Nilsson</surname>
<given-names>Bo</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/289238"/>
</contrib>
</contrib-group>    <aff id="aff1">
<sup>1</sup>
<institution>Rudbeck Laboratory, Department of Immunology, Genetics and Pathology (IGP), Uppsala University</institution>, <addr-line>Uppsala</addr-line>, <country>Sweden</country>
</aff>    <aff id="aff2">
<sup>2</sup>
<institution>Cellular and Molecular Biotechnology Research Institute (CMB), National Institute of Advanced Industrial Science and Technology (AIST)</institution>, <addr-line>Tsukuba</addr-line>, <country>Japan</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Linnaeus Center of Biomaterials Chemistry, Linnaeus University</institution>, <addr-line>Kalmar</addr-line>, <country>Sweden</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Peter F. Zipfel, Leibniz Institute for Natural Product Research and Infection Biology, Germany</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Christian Drouet, U1016 Institut Cochin (INSERM), France; Daniel Ricklin, University of Basel, Switzerland; Thomas Vorup-Jensen, Aarhus University, Denmark</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Bo Nilsson, <email xlink:href="mailto:bo.nilsson@igp.uu.se">bo.nilsson@igp.uu.se</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>03</day>
<month>05</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>891994</elocation-id>
<history>
<date date-type="received">
<day>08</day>
<month>03</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>04</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Adler, Manivel, Fromell, Teramura, Ekdahl and Nilsson</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Adler, Manivel, Fromell, Teramura, Ekdahl and Nilsson</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Complement components have a reputation to be very labile. One of the reasons for this is the spontaneous hydrolysis of the internal thioester that is found in both C3 and C4 (but not in C5). Despite the fact that &#x2248;20,000 papers have been published on human C3 there is still no reliable method to store the protein without generating C3(H<sub>2</sub>O), a fact that may have affected studies of the conformation and function of C3, including recent studies on intracellular C3(H<sub>2</sub>O). The aim of this work was to define the conditions for storage of native C3 and to introduce a robust method that makes C3 almost resistant to the generation of C3(H<sub>2</sub>O). Here, we precipitated native C3 at the isoelectric point in low ionic strength buffer before freezing the protein at -80&#xb0;C. The formation of C3(H<sub>2</sub>O) was determined using cation exchange chromatography and the hemolytic activity of the different C3 preparations was determined using a hemolytic assay for the classical pathway. We show that freezing native C3 in the precipitated form is the best method to avoid loss of function and generation of C3(H<sub>2</sub>O). By contrast, the most efficient way to consistently generate C3(H<sub>2</sub>O) was to incubate native C3 in a buffer at pH 11.0. We conclude that we have defined the optimal storage conditions for storing and maintaining the function of native C3 without generating C3(H<sub>2</sub>O) and also the conditions for consistently generating C3(H<sub>2</sub>O).</p>
</abstract>
<kwd-group>
<kwd>C3</kwd>
<kwd>C3(H2O)</kwd>
<kwd>thioester</kwd>
<kwd>storage</kwd>
<kwd>freezing </kwd>
</kwd-group>    <contract-num rid="cn001"> 2016-01060, 2016-04519, , 2020-05762, 2021-02252</contract-num>    <contract-sponsor id="cn001">Vetenskapsr&#xe5;det<named-content content-type="fundref-id">10.13039/501100004359</named-content>
</contract-sponsor>
<counts>
<fig-count count="3"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="22"/>
<page-count count="7"/>
<word-count count="4218"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>The complement system is initiated through three distinct pathways known as the classical pathway (CP), the lectin pathway (LP) and the alternative pathway (AP). Complement protein C3, was for the first time isolated in the 1960s by M&#xfc;ller-Eberhard et&#xa0;al. (<xref ref-type="bibr" rid="B1">1</xref>) and plays a central role as the first common complement components of all three pathways leading to activation of the terminal pathway. Despite the fact that today (spring 2022) &#x2248;20,000 papers have been published on human C3, there is still no reliable method to store the protein without affecting the conformation and function of the protein, a fact that may affect the interpretation of many studies of C3, including recent studies on intracellular C3 activation (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>).</p>
<p>In the early 1980s, it was demonstrated that C3 (together with C4) contains a unique thioester bond essential for its covalent binding to target surfaces (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>). In the 1980s Pangburn et&#xa0;al. described the spontaneous hydrolysis of the thioester bond within C3 and called this form of C3 &#x201c;C3(H<sub>2</sub>O)&#x201d; (<xref ref-type="bibr" rid="B6">6</xref>&#x2013;<xref ref-type="bibr" rid="B8">8</xref>). C3(H<sub>2</sub>O) is a hemolytic inactive product which displays a &#x201c;C3b-like&#x201d; conformation with an intact &#x3b1;-chain and the C3a domain still remaining (<xref ref-type="bibr" rid="B9">9</xref>). We, and others, have shown that an intermediate form of C3(H<sub>2</sub>O) exists which is conformationally different from both native C3 and C3(H<sub>2</sub>O) (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B10">10</xref>). C3(H<sub>2</sub>O) is susceptible to cleavage by factor I in the presence of factor H and it can form an initial C3 convertase (<xref ref-type="bibr" rid="B8">8</xref>). C3(H<sub>2</sub>O) is generated at a slow rate, concomitant with loss of its hemolytic activity, and the hydrolysis of the internal thiol ester has been estimated to occur at a rate of 0.2-0.4% per hour in plasma (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>). The formation of C3(H<sub>2</sub>O) can be facilitated by treatment of native C3 with e.g., chaotropic agents (e.g., potassium thiocyanate, and guanidine), at the interface of gas and fluid or by slowly freezing and thawing (F/T) C3. A similar form of C3 is also acquired by treating C3 with nucleophiles (e.g., ammonia, and methylamine) (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B13">13</xref>).</p>
<p>Complement has a reputation of being very labile due to the spontaneous hydrolysis of the internal thioester of C3 and C4 (but not in C5 despite their great homology (<xref ref-type="bibr" rid="B13">13</xref>)), which causes a loss of function (e.g., hemolysis) in serum samples but also makes isolated C3 very sensitive to freezing. Today the most common method to store purified native C3 is to freeze it in a physiological buffer. However, when storing native C3 under these conditions it is very important to freeze the protein rapidly at -80&#xb0;C or lower and to avoid repeated F/T cycles since the C3 loses its activity, due to the generation of C3(H<sub>2</sub>O). Studies of C3(H<sub>2</sub>O) have been accelerated due to its involvement in alternative pathway activation and to recent studies of intracellular complement activation (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B14">14</xref>). To avoid heterogeneity with different conformational forms of C3, appropriate handling of C3 in order to control the protein under experimental conditions is essential (<xref ref-type="bibr" rid="B10">10</xref>). Careful characterization of C3(H<sub>2</sub>O) conformations would perhaps have resulted in other conclusions of several previous studies investigating the function and structure of C3(H<sub>2</sub>O). This is underlined by the fact that both maintaining C3 in its native form and the opposite to fully push C3 into its C3(H<sub>2</sub>O) form has been challenging.</p>
<p>The aim of this brief research report is to establish the optimal conditions for storage of native C3 and to introduce a method which protects C3 from being transferred into C3(H<sub>2</sub>O) in its purified form. Based on these studies, we also demonstrate how native C3 can be consistently turned into C3(H<sub>2</sub>O) without contamination with native C3.</p>
</sec>
<sec id="s2">
<title>Material and Methods</title>
<p>CaCl<sub>2</sub>, HCl, KH<sub>2</sub>PO<sub>4</sub>, MgCl<sub>2</sub>, NaCl, and Na<sub>2</sub>HPO<sub>4</sub> were purchased from Merck KGaA (Darmstadt, Germany). PBS tablets (0.14 M NaCl, 2.7 mM KCl, 10 mM phosphate buffer, pH 7.4) were obtained from Medicago AB (Uppsala, Sweden). Bovine serum albumin (BSA), methylamine hydrochloride, EDTA and gelatin was obtained from Sigma Aldrich (St Louis, MO, USA). Buffers were prepared as follows: VB<sup>++</sup> (Veronal-buffered saline) containing 5mM Na-barbiturate, pH 7.4 (145 mM NaCl; 0.15 mM Ca<sup>2+</sup>; 0.5 mM Mg<sup>2+</sup>), GVB<sup>++</sup> (VB<sup>++</sup> with 0.5% w/v gelatin), buffer A for Mono S, 20 mM PBS pH 6.8 (Na<sub>2</sub>HPO<sub>4</sub> 2.054&#xa0;g + KH<sub>2</sub>PO<sub>4</sub> 1.151&#xa0;g + 350 &#xb5;L 37% HCl in 1L MQ-H<sub>2</sub>O), buffer B for Mono S, 20 mM PBS pH 6.8, and 1 M NaCl (Na<sub>2</sub>HPO<sub>4</sub> 2.054&#xa0;g + KH<sub>2</sub>PO<sub>4</sub> 1.151&#xa0;g + 350 &#xb5;L 37% HCl + 58.44&#xa0;g NaCl in 1L MQ-H<sub>2</sub>O). C3-depleted serum and C3b were purchased from Complement Technology (Tyler, TX, USA). The mAb 4SD17.3, as previously described (<xref ref-type="bibr" rid="B15">15</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>), which binds to a neoepitope in free C3a, as well as to the C3a moiety in C3(H<sub>2</sub>O), was used as a coating antibody in the C3(H<sub>2</sub>O) ELISA. Anti-human C3d obtained from Dako (A0064, Glostrup, Denmark), biotinylated in-house (<xref ref-type="bibr" rid="B18">18</xref>), was used as the detection antibody in the C3(H<sub>2</sub>O) ELISA. Streptavidin-HRP was obtained from GE Healthcare (RPN1231, Uppsala, Sweden). TMB (3,3&#xb4;,5,5&#xb4;-tetramethybenzidine) was purchased from Surmodics (Minnesota, USA).</p>
<sec id="s2_1">
<title>Purification and Storage of Native C3</title>
<p>Native C3 was purified in-house from human plasma according to Hammer et&#xa0;al. (<xref ref-type="bibr" rid="B19">19</xref>). After the final step of purification, C3 was precipitated in a low salt and pH buffer for storage by dialysis against a 40 mM phosphate buffer with ionic strength 0.05 (mS) and pH 6.0 at +4&#xb0;C with a buffer volume at least 10-fold higher than the volume of C3. After 24&#xa0;h the buffer was replaced with fresh buffer and dialysis continued for another 24&#xa0;h until a visible precipitate was formed. The stock solution of precipitated native C3 was then suspended (without centrifugation) and aliquoted before storage at -80&#xb0;C. In order to dissolve the precipitated C3, 1-part VB<sup>++</sup> (5x stock solution) was added to 4-parts of precipitated C3 immediately before use.</p>
</sec>
<sec id="s2_2">
<title>C3 Preparations</title>
<p>The samples were prepared as described in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>. The C3 called &#x201c;C3 precipitate&#x201d; was F/T in the precipitated form and &#x201c;native C3&#x201d; is C3 precipitate that has been dissolved, as described above, before being subjected to F/T cycles, methylamine, or different pH conditions. All samples were prepared in 0.5 mL fractions at concentrations of 0.7 mg/mL C3. Slow F/T is defined as F/T from -20&#xb0;C to room temperature (RT), and fast F/T is defined as F/T from -80&#xb0;C to 37&#xb0;C. Note that before running the samples on the column, the precipitated forms were dissolved in VB<sup>++</sup> stock (5x) to a concentration of 0.7 mg/mL. All the different C3 samples were buffer exchanged to buffer A using PD MiniTrap G-25 columns with the gravity protocol (GE Healthcare, Buckinghamshire, UK) before applying them on the Mono S column.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Preparations of the different pure C3 samples analyzed by cation exchange chromatography.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Sample</th>
<th valign="top" align="center">Preparation*</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">
<bold>A</bold>
</td>
<td valign="top" colspan="2" align="left">Native C3, never frozen freshly dissolved C3 precipitate</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>B</bold>
</td>
<td valign="top" colspan="2" align="left">Native C3 incubated in 0.2 M methylamine in VB<sup>++</sup> pH 8.0 for 30&#xa0;min at 37&#xb0;C</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>C</bold>
</td>
<td valign="top" colspan="2" align="left">Native C3 incubated in 0.5 M methylamine in VB<sup>++</sup> pH 8.0 for 30&#xa0;min at 37&#xb0;C</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>D</bold>
</td>
<td valign="top" colspan="2" align="left">C3 precipitate slow F/T from -20&#xb0;C to RT x5</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>E</bold>
</td>
<td valign="top" colspan="2" align="left">Native C3 slow F/T from -20&#xb0;C to RT x1</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>F</bold>
</td>
<td valign="top" colspan="2" align="left">Native C3 slow F/T from -20&#xb0;C to RT x5</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>G</bold>
</td>
<td valign="top" colspan="2" align="left">C3 precipitate fast F/T from -80&#xb0;C to 37&#xb0;C x5</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>H</bold>
</td>
<td valign="top" colspan="2" align="left">Native C3 fast F/T from -80&#xb0;C to 37&#xb0;C x1</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>I</bold>
</td>
<td valign="top" colspan="2" align="left">Native C3 F/T from -80&#xb0;C to 37&#xb0;C x5</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>J</bold>
</td>
<td valign="top" colspan="2" align="left">Native C3 treated in VB<sup>++</sup> pH 5.0 for 30&#xa0;min at 37&#xb0;C</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>K</bold>
</td>
<td valign="top" colspan="2" align="left">Native C3 treated in VB<sup>++</sup> pH 8.0 for 30&#xa0;min at 37&#xb0;C</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>L</bold>
</td>
<td valign="top" colspan="2" align="left">Native C3 treated in VB<sup>++</sup> pH 11.0 for 30&#xa0;min at 37&#xb0;C</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>*F/T, freeze/thaw; RT, room temperature.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s2_3">
<title>Cation Exchange Chromatography</title>
<p>The chromatography was performed using a Mono S 5/50 GL column (GE Healthcare, Bio-Sciences AB, Uppsala, Sweden) with a column volume of 1.0 mL and coupled to the NGC&#x2122; Chromatography System (BioRad, USA). The flow rate was set to 0.5 mL/min at RT throughout the whole separation process. Briefly, the column was first equilibrated with 5 column volumes (CV) buffer A (20 mM phosphate buffer pH 6.8), followed by sample application (0.25 CV). The column was washed with 3 CV of buffer A and then the elution was started using a linear gradient of buffer B ranging from 0 to 0.85M NaCl in 20 mM phosphate buffer pH 6.8 (total volume 17.9 CV). The protein elution was monitored with an UV detector at 280 nm and fractions of 0.5 mL were collected during the elution procedure.</p>
</sec>
<sec id="s2_4">
<title>Hemolytic Assay for the Classical Pathway</title>
<p>A hemolytic assay for CP was performed to investigate the hemolytic activity of C3 treated in pH 11.0, slow and fast F/T C3 precipitate or native C3. Freshly dissolved native C3 was used as a positive control and to create a standard curve and C3b was used as a negative control. First, sheep erythrocytes were sensitized with IgM according to Nilsson and Nilsson (<xref ref-type="bibr" rid="B20">20</xref>). A standard curve was made by spiking freshly dissolved native C3, ranging from 12.5-0.008 &#xb5;g/mL C3, into GVB<sup>++</sup> with 5 &#xb5;L C3-depleted serum (Complement technology) to a final volume of 500 &#xb5;L. C3-depleted sera in GVB<sup>++</sup> without the addition of C3 was used as a blank. The different C3 preparations were spiked into diluted C3-depleted sera in GVB<sup>++</sup> to a final concentration of 0.4 &#xb5;g/mL C3 and a final volume of 500 &#xb5;L. Then, 500 &#xb5;L of 4 x 10<sup>7</sup> IgM sensitized sheep erythrocytes/mL (final concentration; 0.05% sheep erythrocytes) were added to each tube and incubated at 37&#xb0;C on a plate shaker (600 rpm) for 45&#xa0;min. For total lysis 1 mL of pure water was added to 4 x 10<sup>7</sup> cells/mL. The reaction was stopped with 1 mL of cold 10 mM EDTA in VB<sup>++</sup>. The samples were centrifuged at 4&#xb0;C for 10&#xa0;min at 860<italic>g</italic>. Thereafter, 250 &#xb5;L of the supernatant, in duplicate, were transferred into a 96-well microtiter plate and the absorbance was measured at 414 nm. All samples were run in quadruplicate. The absorbance from the blank was removed from the samples and the % of lysis was calculated based on the total lysis.</p>
</sec>
<sec id="s2_5">
<title>Blood Collection and Sample Preparation</title>
<p>Blood was collected from six healthy donors who had not received any medication for a minimum of 10 days prior to donation. For preparation of EDTA plasma, human whole blood was collected in Vacuette<sup>&#xae;</sup> tubes (Greiner Bio-One GmbH, Kremsm&#xfc;nster, Austria) containing K2EDTA (4 mM final concentration) and centrifuged at RT for 15&#xa0;min at 2000<italic>g</italic>. Ethical approval to use human blood was obtained from the regional ethics board in Uppsala (diary nr 2008/264). The plasma was aliquoted into 100 &#xb5;L aliquots and stored either at +4&#xb0;C for 2h (referred to as fresh plasma), or subjected to 1, 3 or 5 F/T cycles, from either -20&#xb0;C to RT or from -80&#xb0;C to 37&#xb0;C, before being analyzed for the generation of C3(H<sub>2</sub>O) using ELISA.</p>
</sec>
<sec id="s2_6">
<title>C3(H<sub>2</sub>O) ELISA</title>
<p>To analyze the generation of C3(H<sub>2</sub>O) in plasma subjected to repeated F/T cycles, an in-house C3(H<sub>2</sub>O) ELISA was used (<xref ref-type="bibr" rid="B11">11</xref>). All washing steps were performed three times with the wash buffer PBS 0.05% Tween 20 and PBS 0.05% Tween20 with 10 mM EDTA and 1% BSA was used as blocking and dilution buffer. All incubations steps were performed at RT on a plate shaker at 700 rpm. In brief, a 96-well Nunc Maxisorp plate (Thermo Fisher Scientific, Denmark) was coated with 100 &#xb5;L of 0.8 &#xb5;g/mL mAb anti-C3a 4SD17.3 in PBS overnight at 4&#xb0;C. The plate was washed and subsequently blocked with 200 &#xb5;L blocking buffer for 60&#xa0;min and then was washed again. Plasma samples were diluted 1/200 and added in duplicate to the plate (100 &#xb5;L/well) and incubated for 60&#xa0;min. For the standard curve, pooled plasma from all donors were diluted 1/200 and spiked with 0.5-0.03 &#xb5;g/mL C3 treated in VB<sup>++</sup>, pH 11.0 (prepared as described in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>), to represent C3(H<sub>2</sub>O). The plate was washed, followed by the addition of 100 &#xb5;L 1 &#xb5;g/mL of the biotinylated detection antibody anti-human C3d (Dako) for 60&#xa0;min. After washing the plate, 100 &#xb5;L of streptavidin-HRP (GE Healthcare Uppsala, Sweden) diluted 1/500 was added for 15&#xa0;min. The plate was again washed followed by the addition of 100 &#xb5;L TMB. Finally, the reaction was stopped using 100 &#xb5;L 1M H<sub>2</sub>SO<sub>4</sub> and the absorbance was measured at 450 nm.</p>
</sec>
<sec id="s2_7">
<title>Statistical Analysis</title>
<p>Data are presented as mean &#xb1; SD or as representative images. Statistical calculations using Freidman&#x2019;s tests followed by Dunn&#x2019;s multiple comparison tests were performed using GraphPad Prism 9 for macOS (GraphPad Software, La Jolla, CA, USA). A <italic>p</italic>-value &lt;0.05 was considered significant.</p>
</sec>
</sec>
<sec id="s3">
<title>Results</title>
<p>Native C3, C3(H<sub>2</sub>O) intermediate, and C3(H<sub>2</sub>O) are conformationally different and can be separated using cation exchange chromatography. In our set-up using a Mono S column, native C3 was eluted at 6 mL (0.25 M NaCl; peak 1), C3(H<sub>2</sub>O) intermediate at an estimated 7 mL (0.35 M NaCl; peak 2), and C3(H<sub>2</sub>O) at an estimated 9.5 mL (0.55 M NaCl; peak 3) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>). Native C3 contained minute amounts of C3(H<sub>2</sub>O) intermediate and C3(H<sub>2</sub>O). The elution profiles of the methylamine treated C3 corresponded to the C3(H<sub>2</sub>O) intermediate and C3(H<sub>2</sub>O) peaks (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1B, C</bold>
</xref>). The more methylamine used, the more of the native C3 had been converted to C3(H<sub>2</sub>O), which was eluted in the last peak (0.2 M compared to 0.5 M). C3 in its precipitated form subjected to five slow F/T cycles (-20&#xb0;C to RT) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1D</bold>
</xref>) did not generate any C3(H<sub>2</sub>O). Whereas native C3 which had been frozen once at -20&#xb0;C (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1E</bold>
</xref>) and native C3 subjected to five slow F/T cycles (-20&#xb0;C to RT) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1F</bold>
</xref>) only had a low level (a few percentage points) of native C3 remaining (peak 1). Precipitated C3 subjected to five fast F/T cycles (-80&#xb0;C to 37&#xb0;C) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1G</bold>
</xref>) did not generate any C3(H<sub>2</sub>O). Native C3 which had been frozen once at -80&#xb0;C (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1H</bold>
</xref>) had native C3 left, however the C3(H<sub>2</sub>O) intermediate and C3(H<sub>2</sub>O) peaks were more prominent compared to the freshly dissolved native C3 and the F/T precipitated C3. Native C3 subjected to five fast F/T cycles (-80&#xb0;C to 37&#xb0;C) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1I</bold>
</xref>) had very little (less than 1%) native C3 left and were mainly in the C3(H<sub>2</sub>O) intermediate and C3(H<sub>2</sub>O) form. Native C3 subjected to a low pH (pH 5.0) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1J</bold>
</xref>) seemed to be stuck in the spin-column membrane, therefore, no C3 is detected, thus indicating that this form of C3 is different. Treating C3 at pH 8.0 for 30&#xa0;min at 37&#xb0;C did not generate C3(H<sub>2</sub>O) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1K</bold>
</xref>). This was also a control for the methylamine treated C3 since it was treated with methylamine in a VB<sup>++</sup> buffer at pH 8.0. However, treating native C3 at pH 11.0 for 30&#xa0;min at 37&#xb0;C clearly pushed all native C3 to the C3(H<sub>2</sub>O) fraction (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1L</bold>
</xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Representative chromatograms of different C3 samples analyzed on a Mono S column eluted with a gradient of 0-0.85 M NaCl. <bold>Peak 1</bold>; native C3, <bold>peak 2</bold>; C3(H<sub>2</sub>O) intermediate, and <bold>peak 3</bold>; C3(H<sub>2</sub>O). <bold>(A)</bold> native C3, <bold>(B)</bold> native C3 treated with 0.2 M methylamine, <bold>(C)</bold> native C3 treated with 0.5 M methylamine, <bold>(D)</bold> C3 in precipitated form F/T five times from -20&#xb0;C to RT, <bold>(E)</bold> native C3 stored frozen once at -20&#xb0;C <bold>(F)</bold> native C3 F/T five times from -20&#xb0;C to RT, <bold>(G)</bold> C3 in precipitated form F/T five times from -80&#xb0;C to 37&#xb0;C, <bold>(H)</bold> native C3 frozen once at -80&#xb0;C, <bold>(I)</bold> native C3 F/T five times from -80&#xb0;C to 37&#xb0;C, <bold>(J)</bold> native C3 treated at pH 5.0, <bold>(K)</bold> native C3 treated at pH 8.0 and <bold>(L)</bold> C3 treated at pH 11.0. F/T, freeze/thaw; RT, room temperature.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-891994-g001.tif"/>
</fig>
<p>The hemolytic assay for the CP (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>) indicated that 0.4 &#xb5;g/mL freshly dissolved native C3 spiked into C3-depleted serum had a hemolytic activity of 70.3% &#xb1; 2.1%, whereas C3b had no hemolytic activity (0.9% &#xb1; 0.7%). Native C3 treated in pH 11.0 was deprived of all hemolytic activity (0.5% &#xb1; 0.2%). C3 precipitate subjected to five slow or fast F/T cycles remained hemolytically active, 70.3% &#xb1; 3.1% and 69.4% &#xb1; 3.0%, respectively. Native C3 subjected to five slow or fast F/T cycles had a decreased hemolytic activity, 12.5% &#xb1; 0.8% and 48.9% &#xb1; 1.9%, respectively.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Hemolytic activity of different C3 preparations (identified by the panel designations in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref> and <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>) analyzed by a hemolytic assay of the classical pathway. The lysis of 0.05% IgM sensitized erythrocytes, i.e., the hemolytic activity of C3, was determined by adding the cells into C3-depleted serum spiked with 0.4 &#xb5;g/mL of native C3 (A), C3b, pH 11- treated C3 (L) or different preparations of F/T C3; precipitated and native C3 subjected to five F/T cycles from -20&#xb0;C to RT (D, F) and C3 subjected to five F/T cycles from -80&#xb0;C to 37&#xb0;C (I, G), respectively. Total lysis was obtained by lysing the cells in pure water. The absorbance was measured at 414 nm. All samples were run in quadruplicates (n = 4). F/T, freeze/thaw; RT, room temperature.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-891994-g002.tif"/>
</fig>
<p>EDTA plasma samples from six different donors were subjected to repeated F/T cycles from -20&#xb0;C to RT and from -80&#xb0;C to 37&#xb0;C and the generation of C3(H<sub>2</sub>O) was measured by ELISA. There was no difference in the C3(H<sub>2</sub>O) generation between fresh and plasma frozen once (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). However, when the plasma was F/T from -20&#xb0;C to RT three times (12.1 &#xb1; 3.8 &#xb5;g/mL, <italic>p</italic>=0.001) and five times (12.0 &#xb1; 3.8 &#xb5;g/mL, <italic>p</italic>=0.005) there was an increase in C3(H<sub>2</sub>O) generation when compared with fresh plasma (3.3 &#xb1; 1.0 &#xb5;g/mL). The corresponding values for -80&#xb0;C to 37&#xb0;C was for F/T three times (4.7 &#xb1; 1.2 &#xb5;g/mL, <italic>p</italic>=0.042) and five times (5.9 &#xb1; 1.7 &#xb5;g/mL, <italic>p</italic>=0.0010) compared with fresh plasma (2.8 &#xb1; 0.3 &#xb5;g/mL).</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Quantification of C3(H<sub>2</sub>O) by ELISA in EDTA plasma (n = 6) that were subjected to repeated F/T cycles: <bold>(A)</bold> -20&#xb0;C to RT; <bold>(B)</bold> -80&#xb0;C to 37&#xb0;C. *: <italic>p</italic>&lt;0.05; **: <italic>p</italic>&lt;0.001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-891994-g003.tif"/>
</fig>
</sec>
<sec id="s4">
<title>Discussion</title>
<sec id="s4_1">
<title>Purified C3</title>
<p>In this report we show that commonly used methods of storage of native C3 are detrimental for the protein conformation and function. This includes freezing and thawing of the protein at -20&#xb0;C and -80&#xb0;C in physiological buffer. From this we can conclude that soluble C3 preparations that are commercially available easily turn into C3(H<sub>2</sub>O) upon storage, especially after repeated F/T cycles, resulting in loss of hemolytic activity. Our investigation confirms that the best alternative at present is to quick-freeze and store the protein in liquid nitrogen in small aliquots avoiding repeated slow F/T of C3.</p>
<p>Our present data show that storage of purified native C3 precipitated at the isoelectric point, pH 5.7 (<xref ref-type="bibr" rid="B1">1</xref>), in a low ionic strength buffer, is the superior method to avoid loss of function and generation of C3(H<sub>2</sub>O) in the preparation. The precipitated form of C3 can be subjected to repeated slow and fast F/T cycles even at -20&#xb0;C without generating C3(H<sub>2</sub>O), i.e., maintaining its full hemolytic activity. This precipitation method is unfortunately not applicable to storage of other thioester-containing proteins such as C4 (data not shown).</p>
<p>Native C3, C3(H<sub>2</sub>O) intermediate, and C3(H<sub>2</sub>O) have been shown to have distinctive conformations and properties (<xref ref-type="bibr" rid="B2">2</xref>). As shown in this study, the amount of native C3, C3(H<sub>2</sub>O) intermediate, and C3(H<sub>2</sub>O) in a sample depends on sample handling and storage. Therefore, when working with native C3/C3(H<sub>2</sub>O) it is important to know which conformations of C3 the preparation contains since it will affect the outcome of the experiments. In native C3, the positively charged C3a domain is hidden, therefore, when separated on the cation exchange chromatography native C3 elutes in the first peak followed by C3(H<sub>2</sub>O) intermediate and lastly C3(H<sub>2</sub>O). Similar elution profiles have been shown by others in previous studies (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B21">21</xref>).</p>
<p>In many publications, including those that initially defined C3(H<sub>2</sub>O) (<xref ref-type="bibr" rid="B6">6</xref>), it is obvious that not all of the C3 is transformed into C3(H<sub>2</sub>O) since some of the &#x3b1;-chain of C3 is still not susceptible to cleavage by factor I. Here, we present the optimal conditions for disrupting the thioester bond in order to consistently generate C3(H<sub>2</sub>O), which include subjecting native C3 to a physiological buffer and repeated F/T cycles at -20&#xb0;C, and even more efficiently, incubating native C3 in a buffer at pH 11.0. At pH 11.0 almost 100% of the thioester bond is broken (<xref ref-type="bibr" rid="B22">22</xref>).</p>
<p>If the transfer to C3(H<sub>2</sub>O) is not complete the possibility still remains that C3(H<sub>2</sub>O) intermediate can go back to the native form of C3 as described by Pangburn et&#xa0;al. (<xref ref-type="bibr" rid="B7">7</xref>). In our previous study (<xref ref-type="bibr" rid="B10">10</xref>), we demonstrated that the C3(H<sub>2</sub>O) intermediate was more resistant to cleavage by FH and FI, while C3(H<sub>2</sub>O) is completely cleaved. We also showed that the intermediate is more efficient at creating a fluid phase initial C3 convertase of the AP compared to C3(H<sub>2</sub>O). Further studies of this form of C3 would highlight its possible role in the physiological function of C3.</p>
</sec>
<sec id="s4_2">
<title>C3 in Plasma</title>
<p>In order to mimic the treatment of clinical patient samples and to investigate the C3(H<sub>2</sub>O) generation in plasma, we subjected EDTA plasma samples from six different donors to repeated F/T cycles. EDTA plasma was chosen to completely block further complement activation. Note that we are aware of that our &#x201c;fresh&#x201d; plasma stored at +4&#xb0;C for 2h while performing the F/T cycles may have generated more C3(H<sub>2</sub>O) than initially existing in the blood. However, there is still an increase of C3(H<sub>2</sub>O) when the plasma F/T, and as also shown by Elvington et&#xa0;al., the generation of C3(H<sub>2</sub>O) when storing serum and plasma at +4&#xb0;C appears to be minimal (<xref ref-type="bibr" rid="B3">3</xref>). The C3(H<sub>2</sub>O) ELISA indicated that C3(H<sub>2</sub>O) is generated in plasma when samples are subjected to repeated F/T cycles. This correlates well with what Elvington et&#xa0;al. also described while using another type of C3(H<sub>2</sub>O) ELISA (<xref ref-type="bibr" rid="B3">3</xref>). The implications are that when designing research experiments with plasma, it is important to be aware of this phenomenon. We also believe that the native C3 in plasma is protected by the surrounding plasma proteins from generating C3(H<sub>2</sub>O), therefore the C3(H<sub>2</sub>O) generation is not as serious as seen in the pure C3 preparations subjected to F/T as described above.</p>
</sec>
</sec>
<sec id="s5">
<title>Conclusions</title>
<p>In order to preserve the function of stored purified native C3, we have shown that native C3 kept in a precipitated form in a low-salt and low-pH buffer at -80&#xb0;C is superior. Although not ideal, it can also be stored in this form at -20&#xb0;C. By contrast, C3(H<sub>2</sub>O) is amply generated upon repeated F/T cycles under physiological conditions in both purified native C3 preparations and in human plasma, in particular, at -20&#xb0;C but also at -80&#xb0;C.</p>
</sec>
<sec id="s6" sec-type="data-availability">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author Contributions</title>
<p>BN, AA, and VM designed the research project. AA and VM performed the experiments. AA and BN wrote the manuscript with editorial assistance from VM, KF, KE, and YT. All authors participated in editing the final manuscript and have read and approved the final manuscript.</p>
</sec>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The Swedish Research Council grants 2016-01060, 2016-04519, 2020-05762, and 2021-02252.</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>M&#xfc;ller-Eberhard</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Nilsson</surname> <given-names>U</given-names>
</name>
<name>
<surname>Aronsson</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Isolation and Characterization of Two &#xdf;1-Glycoproteins of Human Serum</article-title>. <source>J Exp Med</source> (<year>1960</year>) <volume>111</volume>:<page-range>201&#x2013;15</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.111.2.201</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arbore</surname> <given-names>G</given-names>
</name>
<name>
<surname>Kemper</surname> <given-names>C</given-names>
</name>
<name>
<surname>Kolev</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Intracellular Complement &#x2013; the Complosome &#x2013; in Immune Cell Regulation</article-title>. <source>Mol Immunol</source> (<year>2017</year>) <volume>89</volume>:<fpage>2</fpage>&#x2013;<lpage>9</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.molimm.2017.05.012</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elvington</surname> <given-names>M</given-names>
</name>
<name>
<surname>Liszewski</surname> <given-names>MK</given-names>
</name>
<name>
<surname>Bertram</surname> <given-names>P</given-names>
</name>
<name>
<surname>Kulkarni</surname> <given-names>HS</given-names>
</name>
<name>
<surname>Atkinson</surname> <given-names>JP</given-names>
</name>
</person-group>. <article-title>A C3(H20) Recycling Pathway Is a Component of the Intracellular Complement System</article-title>. <source>J Clin Invest</source> (<year>2017</year>) <volume>127</volume>:<page-range>970&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/jci89412</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tack</surname> <given-names>BF</given-names>
</name>
<name>
<surname>Harrison</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Janatova</surname> <given-names>J</given-names>
</name>
<name>
<surname>Thomas</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Prahl</surname> <given-names>JW</given-names>
</name>
</person-group>. <article-title>Evidence for Presence of an Internal Thiolester Bond in Third Component of Human Complement</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>1980</year>) <volume>77</volume>:<page-range>5764&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.77.10.5764</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Isenman</surname> <given-names>DE</given-names>
</name>
</person-group>. <article-title>The Role of the Thioester Bond in C3 and C4 in the Determination of the Conformational and Functional States of the Molecule</article-title>. <source>Ann Ny Acad Sci</source> (<year>1983</year>) <volume>421</volume>:<page-range>277&#x2013;90</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1749-6632.1983.tb18115.x</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pangburn</surname> <given-names>MK</given-names>
</name>
<name>
<surname>M&#xfc;ller-Eberhard</surname> <given-names>HJ</given-names>
</name>
</person-group>. <article-title>Relation of Putative Thioester Bond in C3 to Activation of the Alternative Pathway and the Binding of C3b to Biological Targets of Complement</article-title>. <source>J Exp Med</source> (<year>1980</year>) <volume>152</volume>:<page-range>1102&#x2013;14</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.152.4.1102</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pangburn</surname> <given-names>MK</given-names>
</name>
</person-group>. <article-title>Spontaneous Reformation of the Intramolecular Thioester in Complement Protein C3 and Low Temperature Capture of a Conformational Intermediate Capable of Reformation</article-title>. <source>J Biol Chem</source> (<year>1992</year>) <volume>267</volume>:<page-range>8584&#x2013;90</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S0021-9258(18)42483-0</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Isenman</surname> <given-names>DE</given-names>
</name>
<name>
<surname>Kells</surname> <given-names>DI</given-names>
</name>
<name>
<surname>Cooper</surname> <given-names>NR</given-names>
</name>
<name>
<surname>M&#xfc;ller-Eberhard</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Pangburn</surname> <given-names>MK</given-names>
</name>
</person-group>. <article-title>Nucleophilic Modification of Human Complement Protein C3: Correlation of Conformational Changes With Acquisition of C3b-Like Functional Properties</article-title>. <source>Biochemistry-us</source> (<year>1981</year>) <volume>20</volume>:<page-range>4458&#x2013;67</page-range>. doi: <pub-id pub-id-type="doi">10.1021/bi00518a034</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gros</surname> <given-names>P</given-names>
</name>
<name>
<surname>Milder</surname> <given-names>FJ</given-names>
</name>
<name>
<surname>Janssen</surname> <given-names>BJC</given-names>
</name>
</person-group>. <article-title>Complement Driven by Conformational Changes</article-title>. <source>Nat Rev Immunol</source> (<year>2008</year>) <volume>8</volume>:<fpage>48</fpage>&#x2013;<lpage>58</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri2231</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fromell</surname> <given-names>K</given-names>
</name>
<name>
<surname>Adler</surname> <given-names>A</given-names>
</name>
<name>
<surname>&#xc5;man</surname> <given-names>A</given-names>
</name>
<name>
<surname>Manivel</surname> <given-names>VA</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>S</given-names>
</name>
<name>
<surname>D&#xfc;hrkop</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Assessment of the Role of C3(H2O) in the Alternative Pathway</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>530</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.00530</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ekdahl</surname> <given-names>KN</given-names>
</name>
<name>
<surname>Nilsson</surname> <given-names>B</given-names>
</name>
<name>
<surname>Pekna</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nilsson</surname> <given-names>UR</given-names>
</name>
</person-group>. <article-title>Generation of Ic3 at the Interface Between Blood and Gas</article-title>. <source>Scand J Immunol</source> (<year>1992</year>) <volume>35</volume>:<fpage>85 91</fpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-3083.1992.tb02837.x</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pangburn</surname> <given-names>MK</given-names>
</name>
<name>
<surname>Schreiber</surname> <given-names>RD</given-names>
</name>
<name>
<surname>M&#xfc;ller-Eberhard</surname> <given-names>HJ</given-names>
</name>
</person-group>. <article-title>Formation of the Initial C3 Convertase of the Alternative Complement Pathway. Acquisition of C3b-Like Activities by Spontaneous Hydrolysis of the Putative Thioester in Native C3</article-title>. <source>J Exp Med</source> (<year>1981</year>) <volume>154</volume>:<page-range>856&#x2013;67</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.154.3.856</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="editor">
<name>
<surname>ASK</surname> <given-names>Law</given-names>
</name>
<name>
<surname>AW</surname> <given-names>Dodds</given-names>
</name>
</person-group>. <article-title>C3, C4 and C5: The Thioester Site</article-title>. <source>Biochem Soc T</source> (<year>1990</year>) <volume>18</volume>:<page-range>1155&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1042/bst0181155</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ekdahl</surname> <given-names>KN</given-names>
</name>
<name>
<surname>Mohlin</surname> <given-names>C</given-names>
</name>
<name>
<surname>Adler</surname> <given-names>A</given-names>
</name>
<name>
<surname>&#xc5;man</surname> <given-names>A</given-names>
</name>
<name>
<surname>Manivel</surname> <given-names>VA</given-names>
</name>
<name>
<surname>Sandholm</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Is Generation of C3(H2O) Necessary for Activation of the Alternative Pathway in Real Life</article-title>? <source>Mol Immunol</source> (<year>2019</year>) <volume>114</volume>:<page-range>353&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.molimm.2019.07.032</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nilsson</surname> <given-names>B</given-names>
</name>
<name>
<surname>Grossberger</surname> <given-names>D</given-names>
</name>
<name>
<surname>Ekdahl</surname> <given-names>KN</given-names>
</name>
<name>
<surname>Riegert</surname> <given-names>P</given-names>
</name>
<name>
<surname>Becherer</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Nilsson</surname> <given-names>UR</given-names>
</name>
<etal/>
</person-group>. <article-title>Conformational Differences Between Surface-Bound and Fluid-Phase Complement-Component-C3 Fragments</article-title>. <source>Epitope Mapp by cDNA expression Biochem J</source> (<year>1992</year>) <volume>282</volume>:<page-range>715&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1042/bj2820715</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nilsson</surname> <given-names>B</given-names>
</name>
<name>
<surname>Svensson</surname> <given-names>K-E</given-names>
</name>
<name>
<surname>Borwell</surname> <given-names>P</given-names>
</name>
<name>
<surname>Nilsson</surname> <given-names>UR</given-names>
</name>
</person-group>. <article-title>Production of Mouse Monoclonal Antibodies That Detect Distinct Neoantigenic Epitopes on Bound C3b and Ic3b But Not on the Corresponding Soluble Fragments</article-title>. <source>Mol Immunol</source> (<year>1987</year>) <volume>24</volume>:<page-range>487&#x2013;94</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/0161-5890(87)90023-x</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nilsson</surname> <given-names>B</given-names>
</name>
<name>
<surname>Ekdahl</surname> <given-names>KN</given-names>
</name>
<name>
<surname>Avila</surname> <given-names>D</given-names>
</name>
<name>
<surname>Nilsson</surname> <given-names>UR</given-names>
</name>
<name>
<surname>Lambris</surname> <given-names>JD</given-names>
</name>
</person-group>. <article-title>Neoantigens in Complement Component C3 as Detected by Monoclonal Antibodies</article-title>. <source>Mapp Recognized Epitopes By Synthetic Peptides Biochem J</source> (<year>2005</year>) <volume>268</volume>:<fpage>55</fpage>&#x2013;<lpage>61</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1042/bj2680055</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Johnstone</surname> <given-names>AP</given-names>
</name>
<name>
<surname>Thorpe</surname> <given-names>R</given-names>
</name>
</person-group>. <source>Immunochemistry in Practice. Chapter 11; Coupling Antibodies to Fluorochromes, Enzymes and Biotin</source>. <publisher-loc>Hoboken, USA</publisher-loc>: <publisher-name>Wiley-Blackwell</publisher-name> (<year>1996</year>).</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hammer</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Wirtz</surname> <given-names>GH</given-names>
</name>
<name>
<surname>Renfer</surname> <given-names>L</given-names>
</name>
<name>
<surname>Gresham</surname> <given-names>HD</given-names>
</name>
<name>
<surname>Tack</surname> <given-names>BF</given-names>
</name>
</person-group>. <article-title>Large Scale Isolation of Functionally Active Components of the Human Complement System</article-title>. <source>J Biol Chem</source> (<year>1981</year>) <volume>256</volume>:<fpage>3995</fpage>&#x2013;<lpage>4006</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0021-9258(19)69557-8</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nilsson</surname> <given-names>UR</given-names>
</name>
<name>
<surname>Nilsson</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Simplified Assays of Hemolytic Activity of the Classical and Alternative Complement Pathways</article-title>. <source>J Immunol Methods</source> (<year>1984</year>) <volume>72</volume>:<fpage>49 59</fpage>. doi: <pub-id pub-id-type="doi">10.1016/0022-1759(84)90432-0</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hack</surname> <given-names>CE</given-names>
</name>
<name>
<surname>Paardekooper</surname> <given-names>J</given-names>
</name>
<name>
<surname>Milligen</surname> <given-names>FV</given-names>
</name>
</person-group>. <article-title>Demonstration in Human Plasma of a Form of C3 That has the Conformation of &#x201c;C3b-Like C3&#x201d;</article-title>. <source>J Immunol Baltim Md 1950</source> (<year>1990</year>) <volume>144</volume>:<page-range>4249&#x2013;55</page-range>.</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nilsson</surname> <given-names>B</given-names>
</name>
<name>
<surname>Nilsson</surname> <given-names>UR</given-names>
</name>
</person-group>. <article-title>Antigens of Complement Factor C3 Involved in the Interactions With Factors I and H</article-title>. <source>Scand J Immunol</source> (<year>1986</year>) <volume>23</volume>:<page-range>357&#x2013;63</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-3083.1986.tb01976.x</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>